GSK 4001785A
Alternative Names: altSonflex1-2-3 vaccine; GSK-4001785A; Shigella vaccine - GlaxoSmithKline BiologicalsLatest Information Update: 30 Jan 2025
At a glance
- Originator GlaxoSmithKline Biologicals
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Shigella infections
Most Recent Events
- 13 Nov 2024 Phase-II clinical trials in Shigella infections (Prevention, In infants) in Kenya (IM) (NCT06663436)
- 29 Oct 2024 GlaxoSmithKline plans a phase II trial for Diarrhoea (In children, Prevention) in Kenya (IM) in November 2024 (NCT06663436)
- 27 Sep 2021 Phase-I/II clinical trials in Shigella infections (Prevention, In infants, In children, In adults) in Belgium (IM) after September 2021 (EudraCT2021-000891-12)